IMPACT says the EU approved senaparib while EMA still shows only a September opinion
IMPACT Therapeutics (HKEX: 07630) said on Nov 17, 2026 that the European Commission approved senaparib (Sepalna, EMEA/H/C/006708). EMA's page still shows only the Sept 17 CHMP opinion.
IMPACT Therapeutics (HKEX: 07630) said on November 17, 2026 that the European Commission has granted a marketing authorisation for senaparib (IMP4297; overseas trade name Sepalna; Chinese trade name Paishuning) as maintenance treatment for advanced epithelial ovarian, fallopian-tube and primary peritoneal cancer. Checked the same day, the EMA page for Sepalna (EMEA/H/C/006708) still presents a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on September 17, 2026, and says the product information will be published after the Commission grants the authorisation. The applicant named on that page is SFL Pharmaceuticals Deutschland GmbH. IMPACT’s filing does not give a Commission decision number or name that applicant.
The CHMP summary of opinion states the proposed indication in full: Sepalna as monotherapy for the maintenance treatment of adults with advanced (FIGO stages III and IV) epithelial high-grade ovarian, fallopian-tube or primary peritoneal cancer who are in complete or partial response after first-line platinum-based chemotherapy. The opinion describes the benefit as a progression-free-survival improvement versus placebo, and lists anaemia, leukopenia, neutropenia, thrombocytopenia, nausea and fatigue among the most common side effects. It also says a Commission decision is normally issued 67 days after the opinion, which from September 17 falls on November 23, 2026. IMPACT’s announcement is dated four days before that customary point, and the public EMA record had not yet switched from “opinion” to an authorised medicine.
What today’s filing adds, and what it leaves to the partner
IMPACT says the authorisation makes senaparib the first China-developed PARP inhibitor approved in Europe for first-line maintenance in an all-comer advanced ovarian-cancer population. That “first” comparison is the company’s. The CHMP text itself contains no BRCA restriction: the proposed population is high-grade, FIGO III–IV disease in response after first-line platinum, given as monotherapy. This article has not re-checked the Union Register against every other China-origin PARP.
The same filing says China’s National Medical Products Administration approved senaparib capsules in January 2025 as first-line maintenance for adults with advanced epithelial ovarian, fallopian-tube or primary peritoneal cancer who had a complete or partial response to platinum-based chemotherapy, and that the product was included in the National Reimbursement Drug List in December 2025. The China sentence in the filing does not repeat the words “high-grade” or “FIGO stages III and IV” used in the CHMP indication. The filing is not a side-by-side label comparison, and the Chinese approved wording was not re-read from the NMPA certificate for this update.
A September 18, 2026 joint release from IMPACT and Pharmanovia still described the Commission decision as the step ahead. It said a July 2026 agreement gave Pharmanovia exclusive manufacturing, development and commercialisation rights for senaparib as that maintenance monotherapy in 66 countries, including the 27 European Union member states, the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries in the Middle East and North Africa. The release states no upfront payment, royalty or milestone amount. It attributes the CHMP opinion to the FLAMES phase 3 study and reports an interim progression-free survival result of not reached versus 13.6 months for placebo (hazard ratio 0.43, 95% CI 0.32–0.58). November 17’s Hong Kong filing does not mention Pharmanovia, SFL Pharmaceuticals Deutschland GmbH, or those interim figures. Nothing in the two company documents states whether SFL is a Pharmanovia affiliate.
The November 17 filing still carries the Chapter 18A caution that IMPACT cannot guarantee senaparib will ultimately be marketed in the licensed territories.
The next public record is the Commission decision on the Union Register and the switch of the Sepalna page from opinion to authorised product information. A separate checkpoint is any IMPACT disclosure that names the European marketing-authorisation holder and states the July agreement’s economics.
Checked November 17, 2026 against IMPACT’s English inside-information filing, the EMA Sepalna opinion page, the CHMP summary of positive opinion, and the September 18 IMPACT–Pharmanovia release.